NCT07667335

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-10-20Est. Completion: 2029-07-16

Enrollment target: 27 participants

Locations

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Contact

Rosa Nadal Rios, MD, PhDrnadalri@fredhutch.org 206-598-3300

Other microbiome trials you might be interested in

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerPhase 3Recruiting

Localized Renal Pelvis and Ureter Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis and Ureter Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Renal Pelvis and Ureter Cancer AJCC v7Stage III Ureter Cancer AJCC v7

This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into …

Birmingham, United States

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.